Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CPRX Catalyst Pharmaceutical Partners

已收盘 11-21 16:00:00 EST

21.12

-0.03

-0.14%

盘后21.12

+0.000.00%

19:55 EST

最高21.21	最低20.87	成交量80.77万
今开21.21	昨收21.15	日振幅1.61%
总市值25.19亿	流通市值22.37亿	总股本1.19亿
成交额1,701万	换手率0.76%	流通股本1.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CPRX","market":"US","secType":"STK","nameCN":"Catalyst Pharmaceutical Partners","latestPrice":21.12,"timestamp":1732222800000,"preClose":21.15,"halted":0,"volume":807741,"hourTrading":{"tag":"盘后","latestPrice":21.12,"preClose":21.12,"latestTime":"19:55 EST","volume":24807,"amount":523907.0699,"timestamp":1732236902369},"delay":0,"floatShares":105920631,"shares":119273436,"eps":1.178666,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.03,"latestTime":"11-21 16:00:00 EST","open":21.21,"high":21.21,"low":20.87,"amount":17012304.114003,"amplitude":0.016076,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.178666,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732266000000},"adr":0,"listingDate":1162962000000,"adjPreClose":21.15,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":21.16,"preClose":21.15,"latestTime":"09:28 EST","volume":1141,"amount":24238.73081,"timestamp":1732199329133},"postHourTrading":{"tag":"盘后","latestPrice":21.12,"preClose":21.12,"latestTime":"19:55 EST","volume":24807,"amount":523907.0699,"timestamp":1732236902369},"volumeRatio":0.680784,"impliedVol":0.3887,"impliedVolPercentile":0.3651},"requestUrl":"/m/hq/s/CPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2484960389","title":"美国研究综述-Equifax、Microstrategy、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960389","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484960389?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:10","pubTimestamp":1732000212,"startTime":"0","endTime":"0","summary":"美国研究综述-Equifax、Microstrategy、Netflix路透11月19日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Equifax、Microstrategy 和 Netflix。要闻  * 凯斯百货公司CASY.O：杰富瑞将目标价从 450 美元上调至 470 美元 * Equifax Inc EFX.N：摩根大通将目标价从304美元下调至283美元 * Microstrategy Inc MSTR.O：Benchmark将目标价从300美元上调至450美元 * Netflix Inc NFLX.O：杰富瑞将目标价从800美元上调至1000美元 * Palo Alto Networks Inc PANW.O：杰富瑞将目标价从400美元上调至450美元以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4S3MQ0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOVE","LU1670710661.SGD","LU0109394709.USD","LU1046421795.USD","LU1429558221.USD","KMPR","BK4585","CCCC","KHC","CASY","ACRS","MEOH","MOS","RDDT","WSM","BK4077","CGEM","FNV","LU2326559502.SGD","ARVN","CHPT","PANW","BK4588","MSTR","NFLX","PLUG","VRT","BK4113","LU1571399168.USD","MRNA","CPRT","RGNX","PTCT","FTNT","EHAB","CPRX","KYMR","BECN","QS","LU2249611893.SGD","FENC","LU0106261372.USD","RC","EFX","IDYA","DCOM","LU2237957902.USD","BK4107","IE00BQXX3C00.GBP"],"gpt_icon":1},{"id":"2483383028","title":"Catalyst Pharmaceuticals, Inc.2024财年第三财季实现净利润43.88百万美元，同比增加242.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483383028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483383028?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:02","pubTimestamp":1731600145,"startTime":"0","endTime":"0","summary":"11月15日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为43.88百万美元，同比增加242.65%；其中营业收入为1.29亿美元，同比增加25.24%，每股基本收益为0.37美元。从资产负债表来看，Catalyst Pharmaceuticals, Inc.总负债1.11亿美元，其中短期债务393000.00美元，资产负债比为6.96，流动比率为5.14。机构评级：截至2024年11月15日，当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为31.86美元，其中最低目标价为28.00美元，最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000303a23801c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000303a23801c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"1129925010","title":"异动解读 | 催化剂公司财报利好推动股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1129925010","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129925010?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:46","pubTimestamp":1731033995,"startTime":"0","endTime":"0","summary":"专注罕见病药物研发的催化剂制药公司股价今日盘前大涨6.78%,最高触及18.4美元,引发市场关注。公司上周公布的最新季度业绩显着超预期成为主要推手。财报数据显示,催化剂公司第三季度营收同比大增25.3%至1.287亿美元,高于分析师平均预期。同时归属普通股东的净利润达4388万美元,去年同期为亏损。受业绩超预期利好因素影响,华尔街分析师纷纷上调对该股的评级和目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1173258752","title":"异动解读 | 催化剂公司三季度业绩超预期 盘前大涨6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173258752","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173258752?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:03","pubTimestamp":1730984611,"startTime":"0","endTime":"0","summary":"罕见病药物公司催化剂制药公司今日盘前大涨6.78%,股价最高触及18.4美元,引发市场关注。分析人士认为,公司最新季度业绩超预期是主要原因。该公司上周公布的第三季度财报显示,营收同比大增25.3%至1.287亿美元,超出分析师预期。归属普通股东净利润达4388万美元,去年同期为亏损。凭借财报利好因素,分析师普遍看好催化剂公司长期前景。华尔街分析师给予该股一致\"买入\"评级,平均12个月目标价为30美元,预计仍有16%的上涨空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"1108663842","title":"异动解读 | Catalyst Pharmaceuticals去季度业绩大增股价应声飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1108663842","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108663842?lang=zh_cn&edition=full","pubTime":"2024-11-07 13:17","pubTimestamp":1730956627,"startTime":"0","endTime":"0","summary":"专注于罕见肌肉病研发的Catalyst Pharmaceuticals公司股价周二收盘大涨9.2%。Catalyst最新财报显示,公司第三季度实现营收1.287亿美元,同比大增25.3%;归属普通股股东的净利润4388万美元,去年同期为亏损;每股收益0.35美元,高于分析师平均预期的0.30美元。Catalyst表示,未来将通过开发创新产品不断扩大在神经肌肉疾病领域的覆盖范围。由于财报超预期,华尔街分析师普遍给予Catalyst股票\"买入\"评级,最新一致目标价为30美元,较当前水平有16%的上涨空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CPRX"],"gpt_icon":0},{"id":"2481910511","title":"催化剂制药公司公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481910511","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481910511?lang=zh_cn&edition=full","pubTime":"2024-11-07 13:14","pubTimestamp":1730956486,"startTime":"0","endTime":"0","summary":"催化剂制药公司公布截至 9 月 30 日的季度业绩 - 收益摘要Catalyst Pharmaceuticals Inc CPRX.OQ公布的截至9月30日的季度调整后每股收益为35美分，高于去年同期的每股收益-29美分。华尔街预期为每股收益 28 美分至 33 美分。公司报告的季度净收入为 4388 万美元。Catalyst Pharmaceuticals Inc 的股价本季度上涨了 14.2%，今年迄今为止上涨了 35.1%。华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 30.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4S3ME0OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPRX"],"gpt_icon":0},{"id":"2481834599","title":"Catalyst Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481834599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481834599?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:31","pubTimestamp":1730903488,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时31分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.28%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.91%。其相关个股中，Sonnet Biotherapeutics Holdings, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Sab Biotherapeutics Inc C/Wts 22/10/2026 涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Elevai Labs, Inc.、Zyversa Therapeutics, Inc.较为活跃，换手率分别为1011.50%、97.66%、48.12%，振幅较大的相关个股有Theratechnologies Inc.、Ovid Therapeutics Inc.、Elevai Labs, Inc.，振幅分别为9.37%、8.80%、7.48%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622312898e40d72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622312898e40d72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELAB","BK4183","CPRX"],"gpt_icon":0},{"id":"2460249767","title":"Catalyst Pharmaceuticals, Inc.2024财年第二财季实现净利润40.79百万美元，同比增加8.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460249767","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460249767?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824026,"startTime":"0","endTime":"0","summary":"8月17日，Catalyst Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第二财季净利润为40.79百万美元，同比增加8.02%；其中营业收入为1.23亿美元，同比增加23.52%，每股基本收益为0.35美元。机构评级：截至2024年8月17日，当前有7家机构对Catalyst Pharmaceuticals, Inc.目标价做出预测，其中目标均价为30.14美元，其中最低目标价为26.00美元，最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170003589f31aed1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170003589f31aed1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX"],"gpt_icon":0},{"id":"1103700470","title":"异动解读 | Catalyst Pharmaceuticals财报利好 机构看好前景 股价大涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103700470","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103700470?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:06","pubTimestamp":1723190769,"startTime":"0","endTime":"0","summary":"生物制药公司Catalyst Pharmaceuticals(CPRX.us)今日股价大涨9.98%,报收于17.48美元。公司最新财报数据和机构评级情况或是导致股价大涨的主要原因。\n\nCatalyst Pharmaceuticals最新财报显示,公司实现营业收入98.51百万美元,净利润23.28百万美元,每股收益0.20美元,毛利76.65百万美元。财报数据表现出色,公司业绩持续向好。\n\n此外,机构评级方面,所有7家参与评级的机构均给予该股买入评级,看好公司未来发展前景。公司专注于开发治疗罕见神经肌肉疾病和神经系统疾病的创新疗法,在细分领域具有较强竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2457316479","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨7.67%报17.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457316479","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457316479?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:32","pubTimestamp":1723123952,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时32分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价快速拉升7.67%。截至发稿，该股报17.48美元/股，成交量4.3186万股，换手率0.04%，振幅1.36%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。其相关个股中，Conduit Pharmaceuticals Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Anew Medical, Inc.涨幅较大，Anew Medical, Inc.、Conduit Pharmaceuticals Inc.、Aditxt, Inc.较为活跃，换手率分别为179.48%、174.46%、39.51%，振幅较大的相关个股有Conduit Pharmaceuticals Inc.、Anew Medical, Inc.、Generation Bio Co.，振幅分别为25.33%、15.60%、13.96%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408082132329f1aa453&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408082132329f1aa453&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2457056077","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457056077","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457056077?lang=zh_cn&edition=full","pubTime":"2024-08-06 10:59","pubTimestamp":1722913183,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    将于8月7日公布截至2024年6月30日的财报，预计该公司的季度收入将有所增长。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.49 美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2450367051","title":"Catalyst Pharmaceuticals, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450367051","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450367051?lang=zh_cn&edition=full","pubTime":"2024-07-11 23:33","pubTimestamp":1720711999,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日23时33分，Catalyst Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.05%。Catalyst Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Catalyst Pharmaceuticals, Inc.公司简介：Catalyst Pharmaceuticals Inc是一家生物制药公司。消息层面，截至23时33分，《美银证券维持Catalyst Pharmaceuticals买入评级》资讯为影响Catalyst Pharmaceuticals, Inc.的重要信息。该信息摘要如下：美银证券分析师Jason Gerberry维持$Catalyst Pharmaceuticals $买入评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112333199681c0ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407112333199681c0ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2443278296","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2443278296","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443278296?lang=zh_cn&edition=full","pubTime":"2024-06-14 21:02","pubTimestamp":1718370139,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    将于6月17日公布截至2024年6月30日的季度业绩(估计)，预计该公司的季度收入将出现增长。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.33 美元。6月14日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2441068672","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2441068672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441068672?lang=zh_cn&edition=full","pubTime":"2024-06-07 20:35","pubTimestamp":1717763712,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    预计将在 6 月 10 日公布的截至 0001 年 1 月 1 日的业绩报告(估计) 中显示出季度收入的增长。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.76 美元。6月7日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0},{"id":"2441743421","title":"奥本海默：重申Catalyst Pharmaceuticals(CPRX.US)评级由优于大市调整至优于大市评级, 目标价由29.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441743421","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441743421?lang=zh_cn&edition=full","pubTime":"2024-06-06 22:31","pubTimestamp":1717684278,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CPRX","BK4139"],"gpt_icon":0},{"id":"2440247463","title":"HC Wainwright &amp; Co.：重申Catalyst Pharmaceuticals(CPRX.US)评级，由买入调整至买入评级, 目标价由26.","url":"https://stock-news.laohu8.com/highlight/detail?id=2440247463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440247463?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:27","pubTimestamp":1717410474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","CPRX"],"gpt_icon":0},{"id":"2438371324","title":"Catalyst Pharmaceuticals Inc   预计每股收益 26 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2438371324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438371324?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:01","pubTimestamp":1716901273,"startTime":"0","endTime":"0","summary":"   * Catalyst Pharmaceuticals Inc    预计在5月30日公布的截至2024年6月30日的业绩报告中将显示季度收入增长(预计)    * 根据7位分析师基于LSEG数据的平均估计，这家总部位于佛罗里达州科勒尔盖布尔斯的公司的营收预计将从去年同期的9958万美元增长12.4%，达到1.1196亿美元。)   * LSEG 分析师对 Catalyst Pharmaceuticals Inc 的平均预期为每股收益 26 美分。* 华尔街对 Catalyst Pharmaceuticals Inc 的 12 个月目标价中位数为 26.00 美元，高于其上次收盘价 15.87 美元。5月28日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystpharma.com","stockEarnings":[{"period":"1week","weight":-0.0724},{"period":"1month","weight":0.0062},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.3327},{"period":"1year","weight":0.5393},{"period":"ytd","weight":0.2582}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalyst Pharmaceuticals, Inc.于2006年7月在特拉华州注册成立。该公司是一家商业阶段、以患者为中心的生物制药公司，专注于为患有罕见和难以治疗的疾病的患者提供新的高质量药物的许可、开发和商业化。该公司利用协调一致的勤奋努力，寻找能够改善那些患有罕见或难以治疗的疾病的人的生活的疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.053866},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.012194},{"month":3,"riseRate":0.666667,"avgChangeRate":0.104304},{"month":4,"riseRate":0.388889,"avgChangeRate":0.036621},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.032711},{"month":6,"riseRate":0.555556,"avgChangeRate":0.04776},{"month":7,"riseRate":0.611111,"avgChangeRate":0.118672},{"month":8,"riseRate":0.666667,"avgChangeRate":0.234994},{"month":9,"riseRate":0.388889,"avgChangeRate":-0.026925},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.055859},{"month":11,"riseRate":0.5,"avgChangeRate":0.008162},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.030132}],"exchange":"NASDAQ","name":"Catalyst Pharmaceutical Partners","nameEN":"Catalyst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalyst Pharmaceutical Partners,CPRX,Catalyst Pharmaceutical Partners股票,Catalyst Pharmaceutical Partners股票老虎,Catalyst Pharmaceutical Partners股票老虎国际,Catalyst Pharmaceutical Partners行情,Catalyst Pharmaceutical Partners股票行情,Catalyst Pharmaceutical Partners股价,Catalyst Pharmaceutical Partners股市,Catalyst Pharmaceutical Partners股票价格,Catalyst Pharmaceutical Partners股票交易,Catalyst Pharmaceutical Partners股票购买,Catalyst Pharmaceutical Partners股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalyst Pharmaceutical Partners(CPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalyst Pharmaceutical Partners(CPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}